Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Al-Shahrour F, Alexander D, Wong KK, Van Dyke T.
Weaver Z, et al. Among authors: baran m.
Cancer Res. 2012 Nov 15;72(22):5921-33. doi: 10.1158/0008-5472.CAN-12-0736. Epub 2012 Sep 11.
Cancer Res. 2012.
PMID: 22969147
Free PMC article.